Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14923520 | 0.89 | KHK (0.45) | KHKACHEBCHEPOLBJAK2 | |
| SCHEMBL14928971 | 0.84 | KHK (0.41) | KHKACHEBCHEPOLBJAK2 | |
| SCHEMBL14928834 | 0.83 | KHK (0.44) | KHKPOLBJAK2JAK3CRHR1 | |
| SCHEMBL14928623 | 0.82 | KHK (0.43) | KHKJAK2JAK3KDM4EGAA | |
| SCHEMBL14928858 | 0.82 | KHK (0.43) | KHKJAK2JAK3KDM4EGAA | |
| SCHEMBL14928687 | 0.81 | SOS1 (0.43) | KHKACHEBCHEPOLBJAK2 | |
| SCHEMBL14928839 | 0.81 | KHK (0.43) | KHKPOLBCRHR1PKMPGK1 | |
| SCHEMBL14909736 | 0.80 | ACHE (0.34) | KHKACHEBCHEJAK2JAK3 | |
| SCHEMBL14909735 | 0.80 | ACHE (0.34) | KHKACHEBCHEJAK2JAK3 | |
| SCHEMBL14928413 | 0.80 | KHK (0.42) | KHKACHEBCHEPOLBJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | KHK 2008/4885ACHE 4592/4885BCHE 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.